A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor-Reference-Cited by-同舟云学术

A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor

Published:2020-12-30 Issue:1 Volume:10 Page:30-39
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Agyemang Alex¹,Farrell Colm²,Moore William³,Parkin Jacqueline³

Affiliation:

1. Barts and The London School of Medicine and Dentistry London UK

2. ICON Clinical Research Marlow UK

3. Mereo BioPharma Group plc London UK

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12565

Reference22 articles.

1. Effectiveness of acumapimod oral p38 inhibitor in the treatment of acute severe exacerbations of COPD: results of the AETHER phase II trial;Wedzicha J.;Am. J. Resp. Crit. Care Med.,2018

2. The COPD pipeline XXXVI;Gross N.;Chronic Obstr. Pulm. Dis.,2017

3. p38 MAPK activity is associated with the histological degree of interstitial fibrosis in IgA nephropathy patients

4. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial

5. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antifungal Drugs TDM: Trends and Update;Therapeutic Drug Monitoring;2022-02

2. Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies;Drug Design, Development and Therapy;2021-03